<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Iatrogenic <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> is the limiting factor in the glycemic control of <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>It causes recurrent symptomatic and sometimes, at least temporally, disabling episodes in most people with type 1 <z:mp ids='MP_0002055'>diabetes</z:mp>, as well as in many with advanced type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, iatrogenic <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> precludes maintenance of euglycemia during the lifetime of a person with <z:mp ids='MP_0002055'>diabetes</z:mp> and thus full realization of the well established benefits of glycemic control </plain></SENT>
<SENT sid="3" pm="."><plain>In this article I discuss the clinical problem of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> in <z:mp ids='MP_0002055'>diabetes</z:mp> from the perspective of pathophysiology </plain></SENT>
<SENT sid="4" pm="."><plain>First, the syndromes of defective <z:chebi fb="105" ids="17234">glucose</z:chebi> counterregulation and <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> without warning symptoms (known as <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> unawareness) are described, followed by the unifying concept of <z:hpo ids='HP_0001943'>Hypoglycemia</z:hpo>-Associated Autonomie Failure (HAAF) </plain></SENT>
<SENT sid="5" pm="."><plain>The concept of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo>-associated autonomie failure in <z:mp ids='MP_0002055'>diabetes</z:mp> posits that recurrent antecedent <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> causes both defective <z:chebi fb="105" ids="17234">glucose</z:chebi> counterregulation and <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> unawareness and thus leads to a vicious cycle of <z:hpo ids='HP_0001988'>recurrent hypoglycemia</z:hpo> and further impairment of <z:chebi fb="105" ids="17234">glucose</z:chebi> counterregulation </plain></SENT>
<SENT sid="6" pm="."><plain>The clinical relevance of this phenomenon is now well established, but the mechanisms and mediators remain largely unknown </plain></SENT>
<SENT sid="7" pm="."><plain>The short-term avoidance of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> reverses <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> unawareness in most affected patients </plain></SENT>
<SENT sid="8" pm="."><plain>The ultimate goal of lifelong maintenance of euglycemia in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> remains elusive because of the pharmacokinetic imperfections of <z:hpo ids='HP_0000001'>all</z:hpo> current <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering therapies and the resulting barrier of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Nonetheless, it is now possible both to improve the control of glycemia and to reduce the frequency of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> in many people with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>These results can be accomplished by recognizing the problem of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> applying the principles of aggressive glycemic therapy and reducing the risk factors of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> in people with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>